No Data
Immunome CFO Sells Shares Valued at Over $230,000
Express News | Immunome to Present Updated Results for Ringside Phase 2 Trial of Al102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (Esmo) Congress 2024
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Wedbush Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Leerink Partners Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $38
No Data
No Data
